Headache News and Research RSS Feed - Headache News and Research

In medicine a headache or cephalalgia is a symptom of a number of different conditions of the head. Some of the causes are benign while others are medical emergencies.
Further Reading
Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study

Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study

Eli Lilly and Company and Incyte Corporation today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib met its primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment. [More]
Good first aid kit can help make your vacation perfect

Good first aid kit can help make your vacation perfect

Planning a vacation? Make a little room in your luggage for a travel first aid kit. It won't cost much, and it won't take up much space. Once you reach your destination, you won't need to reach any further than your suitcase to relieve those minor aches and pains that can put a major damper on your plans. [More]
Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) was presented at the 56th American Society of Hematology Annual Meeting and Exposition. [More]
Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy. [More]
New diagnostic system describes symptoms using the image of patient's tongue

New diagnostic system describes symptoms using the image of patient's tongue

Physicians often ask their patients to "Please stick out your tongue". The tongue can betray signs of illness, which combined with other symptoms such as a cough, fever, presence of jaundice, headache or bowel habits, can help the physician offer a diagnosis. For people in remote areas who do not have ready access to a physician, a new diagnostic system is reported in the International Journal of Biomedical Engineering and Technology that works to combine the soft inputs of described symptoms with a digital analysis of an image of the patient's tongue. [More]
Orexo announces positive results from ISTART/006 study

Orexo announces positive results from ISTART/006 study

Orexo US, Inc. announced results from the ISTART/006 study, being presented today at the 25th Annual Meeting and Symposium of the American Academy of Addiction Psychiatry in Aventura, Florida, USA. [More]
Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Novel treatments that harness the body's own immune cells to attack cancer cells demonstrate safe and durable responses in patients with relapsed and treatment-resistant blood cancers, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition. [More]
Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients. [More]
Baxter seeks FDA approval of BAX 855 for treatment of people with hemophilia A

Baxter seeks FDA approval of BAX 855 for treatment of people with hemophilia A

Nektar Therapeutics reported that partner Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) to the United States Food and Drug Administration for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)]. [More]
electroCore CEO highlights the importance of working with stakeholders when launching new technologies

electroCore CEO highlights the importance of working with stakeholders when launching new technologies

JP Errico, founder and CEO of electroCore, speaking at The FT Global Pharmaceutical and Biotechnology Conference in London last week, emphasized the importance of working with each of the major stakeholders, i.e., patients and their advocates, key opinion-leading physicians, and decision-makers within the payor community at the earliest opportunity, particularly in regards to innovative and disruptive technology such as electroCore’s non-invasive vagus nerve stimulation (nVNS). [More]
Endo announces acquisition of rights to Natesto (testosterone nasal gel)

Endo announces acquisition of rights to Natesto (testosterone nasal gel)

Endo International plc, announced today the acquisition of rights to Natesto (testosterone nasal gel), the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma SRL, a wholly-owned subsidiary of Trimel Pharmaceuticals Corporation. [More]
Auxilium Pharmaceuticals presents STENDRA clinical data for ED treatment at SMSNA Scientific Meeting

Auxilium Pharmaceuticals presents STENDRA clinical data for ED treatment at SMSNA Scientific Meeting

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that data were presented regarding the use of STENDRA® (avanafil) tablets for the treatment of erectile dysfunction (ED) at the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA) held in Miami from November 20-23, 2014. [More]
Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS. [More]
Regeneron, Sanofi report positive results from dupilumab Phase 2b study in patients with asthma

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in patients with asthma

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response. [More]
Janssen working with The Union to evaluate SIRTURO (bedaquiline) in patients with MDR-TB

Janssen working with The Union to evaluate SIRTURO (bedaquiline) in patients with MDR-TB

Janssen Research & Development, LLC today announced a collaboration with the International Union Against Tuberculosis and Lung Disease (The Union) to include SIRTURO (bedaquiline) in the STREAM Study. [More]
FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy. [More]
Medical illness common in bipolar disorder

Medical illness common in bipolar disorder

Patients with bipolar disorder have high rates of medical illness, which often exceeds the levels observed in patients with unipolar depression, show results of a UK-based study. [More]
Cellular-level changes in nerve structure and function may contribute to migraine headaches

Cellular-level changes in nerve structure and function may contribute to migraine headaches

A new study shows cellular-level changes in nerve structure and function that may contribute to the development of migraine headaches, reports the November issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS). [More]
Transition Therapeutics presents Phase 2 study of ELND005 drug for bipolar disorder

Transition Therapeutics presents Phase 2 study of ELND005 drug for bipolar disorder

Transition Therapeutics Inc. ("Transition" or the "Company") today announced findings from a Phase 2 study of neuropsychiatric drug candidate, ELND005, as an adjunctive maintenance treatment for bipolar disorder type I patients (BPD). [More]
FDA approves Fluzone High-Dose vaccine sBLA to include efficacy data in Prescribing Information

FDA approves Fluzone High-Dose vaccine sBLA to include efficacy data in Prescribing Information

Sanofi Pasteur, the vaccines division of Sanofi, today announced that the U.S. Food and Drug Administration has approved the supplemental biologics license application (sBLA) for Fluzone High-Dose (Influenza Vaccine) to include efficacy data in the Prescribing Information. [More]